|
|
|
|
|
|
Sponsors and Collaborators: |
Massachusetts General Hospital Dana-Farber Cancer Institute Brigham and Women's Hospital Abbott |
Information provided by: | Massachusetts General Hospital |
ClinicalTrials.gov Identifier: | NCT00181558 |
The main purpose of this study is to look at the effects (good or bad) that Atrasentan given alone and Atrasentan given with Zometa has on levels of bone formation and bone destruction in men with prostate cancer that has spread to the bones.
Condition | Intervention | Phase |
Prostate Cancer Adenocarcinoma of the Prostate |
Drug: Atrasentan Drug: Zoledronic Acid (Zometa) |
Phase II |
MedlinePlus related topics: | Cancer Prostate Cancer |
Drug Information available for: | Zoledronic acid Atrasentan |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Atrasentan and Zometa for Men With Androgen Independent Prostate Cancer Metastatic to Bone: A Randomized Pilot Study |
Estimated Enrollment: | 44 |
Study Start Date: | December 2001 |
Study Completion Date: | December 2006 |
Primary Completion Date: | December 2006 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Massachusetts | |||||
Massachusetts General Hospital | |||||
Boston, Massachusetts, United States, 02114 | |||||
Dana-Farber Cancer Institute | |||||
Boston, Massachusetts, United States, 02115 |
Massachusetts General Hospital |
Dana-Farber Cancer Institute |
Brigham and Women's Hospital |
Abbott |
Principal Investigator: | Matthew Smith, MD, PhD | Massachusetts General Hospital |
Responsible Party: | Massachusetts General Hospital, Boston, MA 02114 ( Matthew R. Smith, MD, PhD ) |
Study ID Numbers: | 01-200 |
First Received: | September 9, 2005 |
Last Updated: | May 19, 2008 |
ClinicalTrials.gov Identifier: | NCT00181558 |
Health Authority: | United States: Institutional Review Board |
|
|
|
|
|